Literature DB >> 21593800

Comparison of glucostatic parameters after hypocaloric diet or bariatric surgery and equivalent weight loss.

Leona Plum1, Leaque Ahmed, Gerardo Febres, Marc Bessler, William Inabnet, Elizabeth Kunreuther, Donald J McMahon, Judith Korner.   

Abstract

Weight-loss independent mechanisms may play an important role in the improvement of glucose homeostasis after Roux-en-Y gastric bypass (RYGB). The objective of this analysis was to determine whether RYGB causes greater improvement in glucostatic parameters as compared with laparoscopic adjustable gastric banding (LAGB) or low calorie diet (LCD) after equivalent weight loss and independent of enteral nutrient passage. Study 1 recruited participants without type 2 diabetes mellitus (T2DM) who underwent LAGB (n = 8) or RYGB (n = 9). Study 2 recruited subjects with T2DM who underwent LCD (n = 7) or RYGB (n = 7). Insulin-supplemented frequently-sampled intravenous glucose tolerance test (fsIVGTT) was performed before and after equivalent weight reduction. MINMOD analysis of insulin sensitivity (Si), acute insulin response to glucose (AIRg) and C-peptide (ACPRg) response to glucose, and insulin secretion normalized to the degree of insulin resistance (disposition index (DI)) were analyzed. Weight loss was comparable in all groups (7.8 ± 0.4%). In Study 1, significant improvement of Si, ACPRg, and DI were observed only after LAGB. In Study 2, Si, ACPRg, and plasma adiponectin increased significantly in the RYGB-DM group but not in LCD. DI improved in both T2DM groups, but the absolute increase was greater after RYGB (258.2 ± 86.6 vs. 55.9 ± 19.9; P < 0.05). Antidiabetic medications were discontinued after RYGB contrasting with 55% reduction in the number of medications after LCD. No intervention affected fasting glucagon-like peptide (GLP)-1, peptide YY (PYY) or ghrelin levels. In conclusion, RYGB produced greater improvement in Si and DI compared with diet at equivalent weight loss in T2DM subjects. Such a beneficial effect was not observed in nondiabetic subjects at this early time-point.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21593800      PMCID: PMC3670603          DOI: 10.1038/oby.2011.134

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  46 in total

1.  GLP-1 and changes in glucose tolerance following gastric bypass surgery in morbidly obese subjects.

Authors:  Rosa Morínigo; Antonio M Lacy; Roser Casamitjana; Salvadora Delgado; Ramon Gomis; Josep Vidal
Journal:  Obes Surg       Date:  2006-12       Impact factor: 4.129

2.  Insulin sensitivity index, acute insulin response, and glucose effectiveness in a population-based sample of 380 young healthy Caucasians. Analysis of the impact of gender, body fat, physical fitness, and life-style factors.

Authors:  J O Clausen; K Borch-Johnsen; H Ibsen; R N Bergman; P Hougaard; K Winther; O Pedersen
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

3.  Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly.

Authors:  Pamela U Freda; Wei Shen; Steven B Heymsfield; Carlos M Reyes-Vidal; Eliza B Geer; Jeffrey N Bruce; Dympna Gallagher
Journal:  J Clin Endocrinol Metab       Date:  2008-03-18       Impact factor: 5.958

Review 4.  Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.

Authors:  Jens Juul Holst; Jesper Gromada
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-08       Impact factor: 4.310

5.  Intermuscular adipose tissue rivals visceral adipose tissue in independent associations with cardiovascular risk.

Authors:  J-E Yim; S Heshka; J Albu; S Heymsfield; P Kuznia; T Harris; D Gallagher
Journal:  Int J Obes (Lond)       Date:  2007-04-24       Impact factor: 5.095

6.  MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test.

Authors:  Ray C Boston; Darko Stefanovski; Peter J Moate; Anne E Sumner; Richard M Watanabe; Richard N Bergman
Journal:  Diabetes Technol Ther       Date:  2003       Impact factor: 6.118

Review 7.  Gastrointestinal surgery as treatment for type 2 diabetes.

Authors:  Tracy-Ann Moo; Francesco Rubino
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2008-04       Impact factor: 3.243

8.  First-phase insulin secretion restoration and differential response to glucose load depending on the route of administration in type 2 diabetic subjects after bariatric surgery.

Authors:  Serenella Salinari; Alessandro Bertuzzi; Simone Asnaghi; Caterina Guidone; Melania Manco; Geltrude Mingrone
Journal:  Diabetes Care       Date:  2008-11-25       Impact factor: 19.112

Review 9.  Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes.

Authors:  Ele Ferrannini; Geltrude Mingrone
Journal:  Diabetes Care       Date:  2009-03       Impact factor: 19.112

10.  Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake.

Authors:  Darleen A Sandoval; Didier Bagnol; Stephen C Woods; David A D'Alessio; Randy J Seeley
Journal:  Diabetes       Date:  2008-05-16       Impact factor: 9.461

View more
  41 in total

Review 1.  Bariatric surgery and the central nervous system.

Authors:  Raghavendra S Rao
Journal:  Obes Surg       Date:  2012-06       Impact factor: 4.129

Review 2.  Gut hormones and leptin: impact on energy control and changes after bariatric surgery--what the future holds.

Authors:  Konstantinos Michalakis; Carel le Roux
Journal:  Obes Surg       Date:  2012-10       Impact factor: 4.129

Review 3.  Can bariatric surgery reduce risk of Alzheimer's disease?

Authors:  Kelly M Stanek; John Gunstad
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-07-04       Impact factor: 5.067

4.  Emerging Pharmacological Targets for the Treatment of Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Type 2 Diabetes.

Authors:  Leigh Goedeke; Rachel J Perry; Gerald I Shulman
Journal:  Annu Rev Pharmacol Toxicol       Date:  2019-01-06       Impact factor: 13.820

Review 5.  Could the improvement of obesity-related co-morbidities depend on modified gut hormones secretion?

Authors:  Carmine Finelli; Maria Carmela Padula; Giuseppe Martelli; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

Review 6.  Neurological consequences of obesity.

Authors:  Phillipe D O'Brien; Lucy M Hinder; Brian C Callaghan; Eva L Feldman
Journal:  Lancet Neurol       Date:  2017-06       Impact factor: 44.182

7.  Acute improvement in insulin resistance after laparoscopic Roux-en-Y gastric bypass: is 3 days enough to correct insulin metabolism?

Authors:  Gil Faria; John Preto; Eduardo Lima da Costa; João Tiago Guimarães; Conceição Calhau; António Taveira-Gomes
Journal:  Obes Surg       Date:  2013-01       Impact factor: 4.129

8.  Gastric bypass surgery with exercise alters plasma microRNAs that predict improvements in cardiometabolic risk.

Authors:  Y O Nunez Lopez; P M Coen; B H Goodpaster; A A Seyhan
Journal:  Int J Obes (Lond)       Date:  2017-03-27       Impact factor: 5.095

Review 9.  Mechanisms of Action of Surgical Interventions on Weight-Related Diseases: the Potential Role of Bile Acids.

Authors:  Mohsen Mazidi; Pedro Paulo P de Caravatto; John R Speakman; Ricardo V Cohen
Journal:  Obes Surg       Date:  2017-03       Impact factor: 4.129

Review 10.  Effects of bariatric surgery on glucose homeostasis and type 2 diabetes.

Authors:  David Bradley; Faidon Magkos; Samuel Klein
Journal:  Gastroenterology       Date:  2012-08-08       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.